



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome



Khalid Sawalha<sup>a,\*</sup>, Mohammed Abozenah<sup>a</sup>, Anis John Kadado<sup>b</sup>, Ayman Battisha<sup>a</sup>, Mohammad Al-Akchar<sup>c</sup>, Colby Salerno<sup>a</sup>, Jaime Hernandez-Montfort<sup>d</sup>, Ashequl M. Islam<sup>b</sup>

<sup>a</sup> Department of Internal Medicine, University of Massachusetts Medical School-Baystate Medical Center, Springfield, MA, United States of America

<sup>b</sup> Department of Cardiology, University of Massachusetts Medical School-Baystate Medical Center, Springfield, MA, United States of America

<sup>c</sup> Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL, United States of America

<sup>d</sup> Heart and Vascular Institute, Cleveland Clinic Florida, Weston, FL 33331, United States of America

### ARTICLE INFO

#### Article history:

Received 22 June 2020

Received in revised form 3 August 2020

Accepted 12 August 2020

#### Keywords:

Myocarditis

COVID-19

Glucocorticoids

Tocilizumab

Pandemic

### ABSTRACT

**Introduction:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also referred to as COVID-19, was declared a pandemic by the World Health Organization in March 2020. The manifestations of COVID-19 are widely variable and range from asymptomatic infection to multi-organ failure and death. Like other viral illnesses, acute myocarditis has been reported to be associated with COVID-19 infection. However, guidelines for the diagnosis of COVID-19 myocarditis have not been established.

**Methods:** Using a combination of search terms in the PubMed/Medline, Ovid Medline and the Cochrane Library databases and manual searches on Google Scholar and the bibliographies of articles identified, we reviewed all cases reported in the English language citing myocarditis associated with COVID-19 infection.

**Results:** Fourteen records comprising a total of fourteen cases that report myocarditis/myopericarditis secondary to COVID-19 infection were identified. There was a male predominance (58%), with the median age of the cases described being 50.4 years. The majority of patients did not have a previously identified comorbid condition (50%), but of those with a past medical history, hypertension was most prevalent (33%). Electrocardiogram findings were variable, and troponin was elevated in 91% of cases. Echocardiography was performed in 83% of cases reduced function was identified in 60%. Endotracheal intubation was performed in the majority of cases. Glucocorticoids were most commonly used in treatment of myocarditis (58%). Majority of patients survived to discharge (81%) and 85% of those that received steroids survived to discharge.

**Conclusion:** Guidelines for diagnosis and management of COVID-19 myocarditis have not been established and our knowledge on management is rapidly changing. The use of glucocorticoids and other agents including IL-6 inhibitors, IVIG and colchicine in COVID-19 myocarditis is debatable. In our review, there appears to be favorable outcomes related to myocarditis treated with steroid therapy. However, until larger scale studies are conducted, treatment approaches have to be made on an individualized case-by-case basis.

© 2020 Elsevier Inc. All rights reserved.

### 1. Introduction

Infection with the novel pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also referred to as COVID-19, was first reported in Wuhan, China in December 2019 and declared a pandemic by the World Health Organization (WHO) in March 2020 [1]. SARS-CoV-2 is one of the zoonotic coronaviruses similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) and believed to

have resulted from a zoonotic transmission to humans from bats [2]. The manifestations of COVID-19 are widely variable and range from asymptomatic infection to multi-organ failure and death. Pulmonary involvement is the most dominant clinical manifestation of COVID-19 including acute respiratory distress syndrome (ARDS) which is associated with higher mortality, up to 52.4% in one series [3]. With rapidly evolving research on COVID-19, cardiovascular manifestations were found to occur in 20–30% of hospitalized patients and associated with worse outcomes [4,5]. COVID-19 related viral myocarditis has been reported in

\* Corresponding author at: University of Massachusetts Medical School-Baystate Medical Center, 759 Chestnut Street, Springfield, MA 01199, United States of America.  
E-mail address: khalid.sawalhamd@baystatehealth.org (K. Sawalha).

multiple case reports and review articles. The mechanism of cardiac injury remains poorly understood which makes management challenging. Multiple institutions have established guidelines for the management of COVID-19 however focus on respiratory distress and ARDS management. No guidelines for the management of myocarditis currently exist. Current practice is limited to case reports and our understanding of the pathophysiology of the disease is still to be determined.

Several reviews on cardiovascular complications have been done recently, yet the management and outcomes of myocarditis was not discussed in details. In this paper, we present an extensive systematic review of the reported cases of COVID-19 related myocarditis. We aim to describe the clinical characteristics and management of currently published COVID-19 myocarditis patients. We also aim to investigate the most common presenting features, workup and outcomes in the reported cases to identify a common pattern to aid in the diagnosis and management.

## 2. Methods

We conducted a systematic search of the medical literature of online databases including PubMed/Medline, Ovid Medline and the Cochrane Library from December 1st 2019 to June 30th 2020. We searched for the following medical subjects heading (MeSH) terms: (((COVID-19 OR coronavirus OR novel coronavirus OR SARS-CoV-2 OR SARS CoV 2))) in combination with terms “Myocarditis”, “Pericarditis”, and “myopericarditis”. We also screened all primary articles bibliography for addition cases. We limited our search to articles written in the English language. We limited our search to case reports only. Our search was in line with PRISMA guidelines and the flowchart in Fig. 1 portrays the search and screening process. A total of 64 records were identified through our literature search. Two reviewers (K.S and M.A) reviewed all retrieved titles, abstracts and manuscripts and identified eight relevant manuscripts. Another four eligible cases were identified by




Fig. 1. PRISMA flowchart showing study screening and selection process.

a manual search on Google scholar, Google search engine, and the bibliographies of the primary articles which resulted in a total of 12 cases. One of the identified manuscripts reported two cases however only one of them reported a case of myocarditis and the second discussed a case of stress cardiomyopathy which was excluded. For each case identified, we collected patient demographics including age and gender and clinical information such as presentation, laboratory results, electrocardiogram, echocardiography and advanced cardiac imaging results.

### 3. Results

Fourteen records comprising a total of fourteen cases that report myocarditis/myopericarditis believed to have occurred secondary to COVID-19 infection were identified from December 1st 2019 to June 30th 2020 [6–19]. There was a male predominance (58%), with the median age of the cases described being 50.4 years. A third (33%) of all cases were younger than 40 years of age. The majority of patients did not have a previously identified comorbid condition (50%), but of those with a past medical history, hypertension was most prevalent (33%). Shortness of breath and/or dyspnea were the commonest presenting features (75%) along with fever (75%). Comorbidities and presenting symptoms were summarized in table-4. Of the 11 cases with documented hemodynamic status, the majority were in shock (64%), with cardiogenic shock being the most commonly identified cause (71% cardiogenic and 29% mixed cardiogenic and septic shock). Examination findings beyond vital signs were rarely reported and so their findings were not included. Around 42% of all patients either presented in acute respiratory distress syndrome (ARDS), or developed it during their hospitalization (Table 1).

Electrocardiogram findings were variable and included diffuse ST-segment elevation, ST-segment depression, and T-wave inversion occurring equally at 25% each. Troponin was elevated in 91% of cases, whereas CK-MB and pro-brain natriuretic peptide (pro-BNP) were checked less frequently. Endomyocardial biopsy was performed in one case which showed virus-negative lymphocytic myocarditis. Echocardiography was performed in most cases (83%) and 60% had reduced ejection fraction. Cardiac tamponade physiology was reported in 20% of all echocardiograms, with diffuse hypokinesis occurring 30% of the time. Advanced cardiac imaging with MRI was performed in 43% of cases which showed diffuse gadolinium enhancement. Coronary artery diagnostic work-up included CT angiography (17%) and invasive coronary angiography (25%). No patients were found to have any obstructive coronary disease. (Table 2).

Around 50% of the patients required Vasopressor support and 25% of them requiring inotropic support. Mechanical support was also utilized (17%), with the commonest modality being extracorporeal membrane oxygenation. Medical management included therapies targeted at COVID-19, therapies for management of myocarditis/myopericarditis, and therapies targeted cytokine storm. Many treatment modalities were also utilized to manage myocarditis/myopericarditis specifically, with glucocorticoids being the most commonly used (58%), followed by immunoglobulin therapy (25%) and colchicine (17%). Of the 7 cases in which glucocorticoid therapy was used, 71% started therapy on day 1 of admission. Additional therapy targeting the cytokine storm were used such as tocilizumab (17%) and interferon (17%) (Table 3).

There was no report of outcomes whatsoever in 3 cases (25%). At the time of submission of the case reports, the majority had survived to discharge (81% of those with reported outcomes) with only a minority of cases not surviving (19% of those with reported outcomes). All of the patients that reportedly passed away were noted to have both ARDS and myocarditis (Table 4).

### 4. Discussion

Our study shows several trends across all cited cases. Hypertension was the most common comorbidity noted amongst cases (33%). Steroids were used in 50% of cases and multiple second-line agents including Tocilizumab (14%), immunoglobulins (21%) and interferon (14%) were used in addition to steroids. Echocardiography showed reduced ejection fraction in the majority of cases. The overall survival rate was 81% and survival rate in those who received steroids was 85%.

SARS-CoV-2 is a beta coronavirus comprised of an enveloped positive single-stranded ribonucleic acid (RNA) structure that belongs to the Coronavirinae subfamily [17]. The virus can invade the human host cell by binding to angiotensin-converting enzyme 2 (ACE2). The ACE2 is a membrane-bound protein that is expressed in many organ tissues, including cardiovascular epithelium, renal and lung tissues. After penetration, viral RNA enters the cell nucleus for replication and apoptosis [20]. The human immune response to the virus is variable which explains the variable clinical presentation. Higher plasma level of cytokines has been found in severe cases such as ARDS [21]. To date, no definitive cure is available for COVID-19 and most of the medications used or currently being studied are targeting the activation of inflammatory cells and proinflammatory cytokines.

Cardiovascular involvement has been prominent in COVID-19 cases. However, despite rapidly developing data and information, little is known about the incidence and outcomes of cardiovascular

**Table 1**  
Baseline characteristics and clinical presentation.

Case	Age and gender	Past medical history	Presenting complaint	Shock?	Acute respiratory distress syndrome?
Cizgici et al.	78 Male	Hypertension	Chest pain and shortness of breath	No	Yes; on arrival
Coyle et al.	57 Male	Hypertension	Shortness of breath, fevers, cough, nausea, diarrhea	Yes; cardiogenic, day 4	Yes; day 3
Dabbagh et al.	67 Female	Non-ischemic cardiomyopathy; LVEF 40%	Cough, mild shortness of breath, left shoulder pain	No	No
Doyen et al.	69 Male	Hypertension	Vomiting and diarrhea; fever, cough, and dyspnea 7 days later	No	Yes
Hu et al.	37 Male	None reported	Chest pain and dyspnea, diarrhea	Yes; cardiogenic, day 1	No
Hua et al.	47 Female	None reported	Breathlessness, chest pain, dry cough, fevers	Yes; cardiogenic, day 1	No
Inciardi et al.	53 Female	None	Severe fatigue, preceded by cough and fever	Yes; cardiogenic, day 1	No
Irabien-Ortiz et al.	59 Female	Hypertension, lymph node tuberculosis, migraines	Fevers, squeezing chest pain	Yes; cardiogenic, day 1	No
Kim et al.	21 Female	None	Fevers, productive cough, shortness of breath, diarrhea	–	–
Radbel et al.	40 Male	None	Fever, dry cough, dyspnea on exertion	Yes; septic day 4, cardiogenic day 5	Yes; day 3
Yuan et al.	33 Male	None reported	Chest pain, fever, myalgias	No	No
Zeng et al.	63 Male	Allergic cough, tobacco smoking	Productive cough, fever, shortness of breath, exertional chest tightness	Yes; cardiogenic day 11, septic day 26	Yes; day 1
Rehman et al.	39 Male	None	Midsternal chest pain	No	No
Sala et al.	43 Female	None	Chest pain and dyspnea	No	No

**Table 2**  
Laboratory investigations and cardiac imaging.

Case report	Electrocardiogram	Cardiac biomarkers	Inflammatory markers	Echocardiogram	Additional cardiac testing
Cizgici et al.	Atrial fibrillation, 150 bpm, diffuse concave ST elevation	Troponin T 998.1 ng/L	CRP 94.6 mg/L		Coronary angiography without obstructive CAD CT chest showed small pericardial effusion suggestive of pericarditis
Coyle et al.	Sinus tachycardia, no ST/T changes	Troponin I 7.33 peak (day 3), pro-BNP 1300 peak (day 5)	CRP 20.7 mg/dL peak (day 5), IL-6 18	Diffuse hypokinesia with relative apical sparing, LVEF 35–40%, no pericardial effusion	Cardiac MRI with LVEF 82%, diffuse bi-ventricular and bi-atrial edema, and small area of late gadolinium enhancement
Dabbagh et al.	Low voltage limb leads, non-specific ST changes	Troponin I < 18 ng/L, pro-BNP 54 pg/mL	CRP 15.9 mg/dL, IL-6 8 pg/mL	Large circumferential pleural effusion, signs of early right ventricular diastolic collapse, dilated but collapsing inferior vena cava, LVEF 40%	–
Doyen et al.	Diffuse T-wave inversion, LVH	Troponin I 9002 ng/L	–	Mild LVH, LVEF normal	Coronary angiography negative Cardiac MRI with subepicardial late gadolinium enhancement (apex and inferolateral wall)
Hu et al.	ST elevation leads III and aVF, ST depression V4-V6	Troponin T > 10,000 ng/L CK-MB 112.9 ng/L, pro-BNP 21,025 ng/L	–	Enlarged heart, LVEF 27%, 2 mm pericardial effusion	CTA coronaries without stenosis
Hua et al.	Sinus tachycardia, concave inferolateral ST elevation	Troponin T peak 253 ng/L	–	LVEF normal, pericardial effusion 11 mm, no tamponade; repeat Echo with 20 mm effusion and tamponade	–
Inciardi et al.	Diffuse ST elevation, ST depression and T inversion V1 and aVR	Troponin T 0.89 ng/mL peak, CK-MB 39.9 ng/mL peak, BNP 8465 pg/mL peak	CRP 1.3 mg/dL	Diffuse hypokinesia, LVEF 40%, circumferential pericardial effusion 11 mm, no tamponade	Coronary angiography without obstructive CAD Cardiac MRI fulfilled Lake Louise criteria
Irabien-Ortiz et al.	Diffuse ST elevation and PR depression	Troponin T 1100 ng/dL peak, BNP 4421 ng/L	CRP 10 mg/L	Concentric hypertrophy, diminished LV volumes, normal LVEF, moderate pericardial effusion, no tamponade	–
Kim et al.	Non-specific IV conduction delay, multiple PVCs, T wave inversions in II, III, aVF, V3-V6	Troponin I 1.26 ng/mL, BNP 1929 pg/mL	–	Severe LV dysfunction	Cardiac CT/CTA with normal coronary arteries; edematous myocardium and subendocardial perfusion defect lateral LV Cardiac MRI with high T2 signal intensity and increased T1 extracellular volume
Radbel et al.	ST depressions in V4-V6; day 5	Troponin T < 0.01 ng/mL day 4; rose to 5.21 day 5	CRP 18.3 mg/dL, IL-6 74.3 pg/mL	Mild global hypokinesia	–
Yuan et al.	Ventricular tachycardia	–	–	–	Cardiac MRI day 3 with increased T2WI signal intensity, normal early and late gadolinium enhancement
Zeng et al.	Sinus tachycardia, left axis deviation, no ST elevation	Troponin I 11.37 g/L peak, myoglobin >600 ng/mL peak, BNP 22,500 pg/mL peak	IL-6 272.4 pg/mL peak	Enlarged LV, diffuse myocardial dyskinesia, LVEF 32%, pulmonary hypertension, normal RV function, no pericardial effusion	–
Rehman et al.	1 to 2 mm ST elevations in lead I and aVL, ST depression in aVR, mild J-point elevation, and T-wave inversion in leads II, III and aVF	Troponin 5.97 ng/mL	ESR 44 mm/h, LDH 926 units/L, CRP 3.3 mg/dL, CPK 366unit/L	No wall motion abnormalities and normal ejection fraction at 55%–60%	Coronary angiography without obstructive CAD
Sala et al.	Mild ST-segment elevation in leads V1–V2 and aVR, reciprocal ST depression in V4–V6	Troponin T 135 ng/L, NT-proBNP 512 pg/mL	–	Mild left ventricular systolic dysfunction (LVEF 43%) with inferolateral wall hypokinesia	Cardiac MRI showed diffuse myocardial edema and wall pseudo-hypertrophy on T1 Endomyocardial biopsy: diffuse T-lymphocytic inflammatory infiltrates (CD3+ >7/mm <sup>2</sup> ) with huge interstitial edema and limited foci of necrosis

CAD: coronary artery disease; LV: left ventricle; LVEF: left ventricular ejection fraction; MRI: magnetic resonance imaging; RV: right ventricle.

manifestations in COVID-19. There are several cardiac presentations that have been noted, including acute myocardial infarction, acute heart failure, cardiogenic shock, myocarditis, and malignant arrhythmia [22]. Patients with underlying cardiovascular disease (CVD) have a higher risk of developing cardiac injury. In a single-center retrospective study from Wuhan including 187 patients, the mortality rate was higher in patients with underlying CVD compared to patients without CVD (54.5% vs 13.2%). It also showed that 37.5% of patients who died had cardiac injury with elevated troponin and mortality was 69.4% in those with a history of CVD [23]. In most studies, cardiac injury was evident by elevated troponin and pro-BNP. The levels of these markers were higher in critically ill patients admitted to the ICU [24]. Given that the exact

mechanism of cardiac involvement is not well understood, management of this entity is more challenging. Like other viral illnesses, acute myocarditis has been reported to be associated with COVID-19 infection. Guidelines for the diagnosis of COVID-19 myocarditis have not been established. Current literature on this manifestation is limited to case reports and a small number of patients in cohort studies. However, a workup including cardiac biomarkers and electrocardiogram are initially recommended [25]. Our results revealed that ECG changes were non-specific and highly variable. This is consistent with non-specific ECG findings in myocarditis cited in the literature [26]. Serial ECGs may be a tool to provide a relatively quick, cost-effective, and non-invasive means at outlining and intervening in early stages of the disease process.

**Table 3**  
Management and outcomes.

Case	Vasopressor/mechanical support	Glucocorticoid therapy	Immunoglobulin therapy	IV tocilizumab	Outcome
Cizgici et al.	–	–	–	–	Transferred back to hospital
Coyle et al.	Milrinone day 4, norepinephrine day 4	IV methylprednisolone 500 mg daily x 4 days, followed by taper	–	400 mg once, day 5	Discharged on day 19
Dabbagh et al.	–	Glucocorticoids	–	–	Discharged
Doyen et al.	–	IV hydrocortisone for 9 days; started day 11	–	–	Discharged from ICU after 3 weeks
Hu et al.	Norepinephrine and milrinone	IV methylprednisolone 200 mg daily x 4 days	IVIG 20 g daily x 4 days	–	Improved
Hua et al.	Vasopressors	–	–	–	Improved/survived
Inciardi et al.	Dobutamine	IV methylprednisolone 1 mg/kg x 3 days	–	–	Improved
Irabien-Ortiz et al.	Norepinephrine; additional vasopressors unspecified IABP and ECMO day 1	IV methylprednisolone 500 mg daily at tapering doses x 14 days	IVIG 80 mg daily x 4 days Interferon- $\beta$ 0.25 mg q48 hours	–	Not reported
Kim et al.	–	–	–	–	Not reported
Radbel et al.	Norepinephrine day 4	–	–	400 mg once, day 4	Passed away day 7
Yuan et al.	–	–	–	–	Discharged
Zeng et al.	ECMO day 11 Vasopressors day 26	IV methylprednisolone;	IVIG Interferon- $\alpha$ 1b;	–	Passed away day 33
Rehman et al.	–	–	–	–	Recovery
Sala et al.	–	–	–	–	Recovery

ECMO: extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump IVIG: intravenous immunoglobulin.

Echocardiography is an important tool in evaluating structural and functional changes secondary to myocarditis [27,28]. However, no specific echocardiographic features of myocarditis exist, but it allows the physician to exclude other causes of heart failure, pericardial effusion, and intracavitary thrombi [29]. Patterns consistent with dilated, hypertrophic, and ischemic cardiomyopathies have all described in biopsy-proven myocarditis [30]. In our study, no trend was appreciated with regards to echocardiogram findings on presentation, with 50% showing reduced ejection fraction and 42% showing evidence of pericardial effusion. Diffuse hypokinesis was also seen in 25% of cases. Cardiac MRI is the noninvasive gold standard test for myocarditis. It was done in six of the reported cases of which all showed gadolinium enhancement and two showed evidence of myocarditis as fulfilled by the Lake Louis criteria for MRI based diagnosis of myocarditis.

The mechanism of cardiac injury in COVID-19 remains poorly understood. There are several potential hypotheses on the pathogenesis of COVID-19 myocarditis including: (a) direct damage to cardiomyocytes by circulating virus through binding to ACE2 receptors [31] (b) severe cytokine release syndrome by dysregulated response by types 1 and 2 helper T cells which leads to severe systemic inflammatory response resulting in cardiomyocytes hypoxia and apoptosis, and (c) overactivation of the autoimmune system with possible interferon mediated hyperactivation of innate and adaptive immune systems [32,33].

To date, there is no clear data on the role of ACE2 receptors in the pathogenesis of COVID 19 myocarditis, but may serve as a portal for entry of COVID-19. A previous study from the SARS-CoV outbreak in Toronto showed that the virus RNA was detected in 35% of autopsied hearts [34]. Another animal study done in 2009 showed that SARS-CoV pneumonia can increase expression of ACE2 receptors and cause myocardial injury [35]. The role of these receptors has led to postulations on the potential benefits or harms of the use of angiotensin-converting enzyme inhibitors. However, given the lack of conclusive data, continuation of clinically indicated angiotensin receptor blocker medications is recommended, unless clinically contraindicated [36].

Another proposed hypothesis of the pathogenesis of myocarditis in COVID-19 is severe systemic inflammation and cytokine storm. Cytokine storm is an exaggerated immune response to stimulus or pathogen

and is associated with rapid deterioration and high mortality. Several studies on previous coronavirus outbreaks such as MERS-CoV and SARS-CoV revealed that serum cytokine and chemokine levels are significantly higher especially in critically ill patients and patients who developed ARDS [37]. When a host is infected with COVID-19, the primary immune system responds by secretion of interferons (IFNs) and proinflammatory cytokines. The release of interferons (the first line defense against viral infections) is delayed in the early stages infection, allowing to continue replicating and attracting inflammatory cells to tissue, lung or cardiac, which results in severe inflammation.

The current data on the use of glucocorticoids in COVID-19 infection remains controversial and to our knowledge, no current studies have been conducted to assess the efficacy of corticosteroid therapy on COVID-19 myocarditis. Corticosteroid therapy was ineffective in treating viral myocarditis according to a Cochrane systematic review published in 2013 [40]. Furthermore, it has been reported that corticosteroid therapy might delay the clearance of the virus. In a study that was recently done on COVID-19 patients, the duration of viral RNA detection for oropharyngeal swabs and feces was longer in patients who were treated with corticosteroids [41]. Moreover, there is concern for increasing secondary infection and adrenal insufficiency as a result of steroid therapy. Two studies from China showed that IV methylprednisone has no significant benefit in COVID-19 patients [42] and was associated with higher ICU admissions [43]. However, these findings might be confounded given that steroids were used on sicker patients and likely for separate treatment purposes. On the contrary, a study from Wuhan involving 84 -patients with ARDS secondary to COVID-19, administration of corticosteroids decreased the risk of mortality [3]. Additionally, A recent press release from a large clinical trial on COVID-19 patients, the RECOVERY (Randomized Evaluation of COVID-19 tHERapY), Dexamethasone was shown to reduce mortality in one third of the ventilated patients (rate ratio 0.65 [95% CI 0.48 to 0.88];  $p = 0.0003$ ). In our review, five out of seven patients who were treated with corticosteroid recovered; one passed away and the other case did not report outcomes. We cannot confirm if it is due to a true treatment effect or by chance only, yet based on recent data, steroid might be associated with favorable outcomes in critically ill COVID19 patients [44].

**Table 4**  
Grouped characteristics and outcomes identified across cases.

N = 14 cases; mean age: 50.4 years; males 58%, females 42%	N (%)
<b>Comorbidities</b>	
None	7 (50)
Cardiomyopathy	1 (8)
Hypertension	4 (33)
Smoking	1 (8)
Other (lymph node tuberculosis, allergies)	2 (17)
<b>Presenting symptoms</b>	
Chest pain	8 (57)
Shortness of breath/dyspnea	10 (71)
Fever	9 (75)
Upper respiratory tract symptoms (cough mainly)	8 (67)
Gastrointestinal symptoms	4 (33)
<b>Shock</b>	<b>7 (58)</b>
Purely cardiogenic	5 (42)
Mixed cardiogenic and septic	2 (17)
<b>ARDS</b>	<b>5 (42)</b>
<b>EKG findings</b>	<b>14 (100)</b>
ST elevation; in a coronary vessel distribution	4 (28)
ST elevation; diffuse	3 (25)
ST depression	3 (25)
T-wave inversion	3 (25)
Arrhythmia	2 (17)
<b>Cardiac biomarkers</b>	<b>13 (93)</b>
Elevated troponin (I or T)	12 (86)
Elevated CK-MB	2 (17)
Elevated pro-BNP	6 (50)
<b>Inflammatory markers</b>	<b>7 (58)</b>
Elevated CRP	7 (50); 100% of all cases where it was reported
Elevated IL-6	4 (33); 100% of all cases where it was reported
<b>Echocardiogram findings</b>	<b>12 (83)</b>
Reduced left ventricular ejection fraction (LVEF)	6 (50)
Pericardial effusion	5 (42)
<b>Cardiac CT/CTA</b>	<b>3 (21)</b>
<b>Cardiac MRI findings</b>	<b>6 (43)</b>
<b>Coronary angiography</b>	<b>4 (29)</b>
<b>Endomyocardial biopsy</b>	<b>1 (7)</b>
<b>Management</b>	
Endotracheal intubation and ventilation	7 (50)
Vasopressor support	6 (43)
Inotropic support	3 (21)
Hydroxychloroquine	5 (36)
Azithromycin	2 (14)
Glucocorticoids	7 (50)
Immunoglobulin	3 (21)
Interferon	2 (14)
Tocilizumab	2 (14)
Mechanical support	2 (14)
<b>Combined therapy</b>	
Corticosteroid only	3 (21); 100% survival amongst those who received corticosteroids only
Corticosteroid + IVIG	3 (21); 66% survival amongst those who received corticosteroids + IVIG therapy
Corticosteroid + tocilizumab	1 (7); patient survived to discharge
Tocilizumab alone	1 (7); patient ultimately died
<b>Outcome at time of case submission; not reported in 3 cases (Cizgici et al., Hua et al., and Kim et al.)</b>	
Survival	9 (64); 81% of all reported outcomes
Death	2 (14); 18% of all reported outcomes

Bold italic is the main variable and normal font is subanalysis of the variable.

Intravenous immunoglobulin was used in three reported cases with variable outcomes. There is strong evidence on the efficacy of IVIG in the treatment of acute myocarditis. A meta-analysis published in 2019 comparing IVIG to corticosteroid for acute myocarditis showed that IVIG therapy improved mortality and recovery of left ventricular function [45]. It was difficult to notice a specific trend on IVIG in our review because it was used only in three patients

and more studies are needed to prove its efficacy on COVID-19 myocarditis.

Tocilizumab is an IL-6 receptor antagonist that is used more commonly in rheumatoid arthritis treatment. It is also approved to be used for cytokine release syndrome based on multiple studies that proved its efficacy [46]. In a single center case series including 15 patients, 11 patients improved or stabilized after starting tocilizumab however, the study included a small number of patients and reported the outcomes after 7 days post treatment only [47]. In the reported cases, four report high IL-6 levels, and 50% of those with high IL-6 levels received Tocilizumab with variable outcomes resulting. There are currently several ongoing clinical trials [48–50] evaluating the efficacy of IL-6 antagonists in COVID-19 patients.

Guidelines for diagnosis and management of COVID-19 myocarditis have not been established and our knowledge on management is rapidly changing. Several treatments have been used in COVID-19 myocarditis based on our understanding of the pathogenesis and from previous experience in treating viral and fulminant myocarditis. Since hyperinflammation and cytokine release syndrome are a likely mechanism of injury in COVID-19 myocarditis, glucocorticoids have been used despite lack of proven clinical efficacy. Other possible treatments currently under study are plasma exchange therapy, immunosuppression with IVIG and cytokine inhibitors and antiviral agents such as Remdesivir. In early trial results, Remdesivir, was found to be superior to placebo in shortening the time to recovery in adults hospitalized with COVID-19 [51]. It was also found to prevent and reduce disease severity in MERS coronavirus in primates [52]. Until prospective studies and trials establish guidelines for the management of COVID-19 myocarditis, treatment has to be catered to individual case presentations.

## 5. Limitations

The limitations of this study are characteristic to studies based on case reports. First, our study is limited to cases reports which imparts potential selection bias since reported cases are usually unique cases in presentation and management. Since the COVID-19 pandemic impacted routine clinical practice and diagnostic approaches, many cases did not undergo further diagnostic workup done such as cardiac MRI and endomyocardial biopsy. In addition, publication bias on the part of authors reporting these cases is another factor to account for. Despite these limitations, we believe the use of case reports in our review is fundamental in detecting trends and generating hypotheses.

## 6. Conclusion

Our knowledge on the complications and management of COVID-19 is exponentially growing. Myocardial injury and myocarditis have been shown to be associated with higher morbidity and mortality. Despite the rapidly growing research on management of COVID-19 and its complications, there are many unanswered questions and areas to explore. Currently, most of the ongoing research is focusing on the respiratory complications of COVID-19 and little is known about myocarditis management. The use of glucocorticoids in COVID-19 myocarditis is debatable. In our review, there appears to be favorable outcomes related to myocarditis treated with steroid therapy. However, until larger scale studies are conducted, treatment approaches have to be made on an individualized case-by-case basis.

## Primary funding source

None.

## Declaration of competing interest

None.

## References

- [1] World Health Organization. Rolling updates on coronavirus disease (COVID-19). <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>; March 13, 2020.
- [2] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *Int J Infect Dis.* 2016;49:129–33.
- [3] Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med.* 2020;180:934–43.
- [4] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol.* 2020; <https://doi.org/10.1001/jamacardio.2020.0950>.
- [5] Cizgici AY, Agus HZ, Yildiz M. COVID-19 myopericarditis: it should be kept in mind in today's conditions. *Am J Emerg Med.* 2020. <https://doi.org/10.1016/j.ajem.2020.04.080>.
- [6] Coyle J, Igbinomwanhia E, Sanchez-Nadales A, Danciu S, Chu C, Shah N. A recovered case of COVID-19 myocarditis and ARDS treated with corticosteroids, tocilizumab, and experimental AT-001. *JACC: Case Rep.* 2020;38:1547.e5–6. <https://doi.org/10.1016/j.jaccas.2020.04.025>.
- [7] Dabbagh MF, Aurora L, D'Souza P, Weinmann AJ, Bhargava P, Basir MB. Cardiac Tamponade secondary to COVID-19. *JACC: Case Rep.* 2020;2:1326–30. <https://doi.org/10.1016/j.jaccas.2020.04.009>.
- [8] Doyen D, Mocerri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. *Lancet.* 2020;395:1516. [https://doi.org/10.1016/s0140-6736\(20\)30912-0](https://doi.org/10.1016/s0140-6736(20)30912-0).
- [9] Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. *Eur Heart J.* 2021;42:206. <https://doi.org/10.1093/eurheartj/ehaa190>.
- [10] Hua A, O'Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. *Eur Heart J.* 2020;41:2130. <https://doi.org/10.1093/eurheartj/ehaa253>.
- [11] Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* 2020; <https://doi.org/10.1001/jamacardio.2020.1096>.
- [12] Irabien-Ortiz Á, Carreras-Mora J, Sionis A, Pàmies J, Montiel J, Tauron M. Fulminant myocarditis due to COVID-19. *Revista Española De Cardiología (English Edition).* 2020;73:503–4. <https://doi.org/10.1016/j.rec.2020.04.005>.
- [13] Kim I, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. *Eur Heart J.* 2020;41:1859. <https://doi.org/10.1093/eurheartj/ehaa288>.
- [14] Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome. *Chest.* 2020;158:e15–9. <https://doi.org/10.1016/j.chest.2020.04.024>.
- [15] Yuan W, Tang X, Zhao X. An 'asymptomatic' driver with COVID-19: atypical suspected myocarditis by SARS-CoV-2. *Cardiovasc Diag Ther.* 2020;10:242–3. <https://doi.org/10.21037/cdt.2020.03.08>.
- [16] Zeng JH, Liu Y, Yuan J, Wang F, Wu W, Li J, et al. First Case of COVID-19 Infection With Fulminant Myocarditis Complication: Case Report and Insights; 2020. <https://doi.org/10.20944/preprints202003.0180.v1>.
- [17] Brian DA, Baric RS. Coronavirus genome structure and replication. *Curr Top Microbiol Immunol.* 2005;287:1–30. [https://doi.org/10.1007/3-540-26765-4\\_1](https://doi.org/10.1007/3-540-26765-4_1).
- [18] Rehman M, Gondal A, Rehman NU. Atypical manifestation of COVID-19-induced myocarditis. *Cureus.* 2020 Jun;12:e8685.
- [19] Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. *Eur Heart J.* 2020 May 14;41:1861–2.
- [20] Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. *Clin Immunol.* 2020;215:108427. <https://doi.org/10.1016/j.clim.2020.108427>.
- [21] Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. *Immunol Res.* 2014;59:118–28. <https://doi.org/10.1007/s12026-014-8534-z>.
- [22] Fried JA, Ramasubbu K, Bhatt R, Topkara VK, Clerkin KJ, Horn E, et al. The variety of cardiovascular presentations of COVID-19. *Circulation.* 2020;141:1930–6.
- [23] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395:1054–62. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
- [24] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* 2020;5:1–8.
- [25] Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. *Circ Res.* 2016 Feb 5;118:496–514.
- [26] Nieminen MS, Heikkilä J, Karjalainen J. Echocardiography in acute infectious myocarditis: relation to clinical and electrocardiographic findings. *Am J Cardiol.* 1984 May 1;53:1331–7.
- [27] Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, et al. Echocardiographic findings in fulminant and acute myocarditis. *J Am Coll Cardiol.* 2000 Jul 1;36:227–32.
- [28] Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. *J Am Coll Cardiol.* 2012 Feb 28;59:779–92.
- [29] Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. *J Am Coll Cardiol.* 2007 Nov 6;50:1914–31.
- [30] Blauwet LA, Cooper LT. Myocarditis. *Prog Cardiovasc Dis.* 2010 Jan 1;52:274–88.
- [31] Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. *Circ Res.* 2020 May 8;126:1456–74.
- [32] Wang CH, Liu CY, Wan YL, Chou CL, Huang KH, Lin HC, et al. Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. *Respir Res.* 2005;6:42. <https://doi.org/10.1186/1465-9921-6-42>.
- [33] Channappanavar R, Fehr AR, Zheng J, C Wohlford-Lenane, Abrahante JE, Mack M, et al. IFN- $\lambda$  response timing relative to virus replication determines MERS coronavirus infection outcomes. *J Clin Invest.* 2019;129:3625–39. <https://doi.org/10.1172/JCI126363>.
- [34] Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. *JAMA.* 2003;289:2801–9. <https://doi.org/10.1001/jama.289.21.JOC30885>. Erratum in: *JAMA.* 2003;290:334.
- [35] Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. *Eur J Clin Invest.* 2009;39:618–25. <https://doi.org/10.1111/j.1365-2362.2009.02153.x>.
- [36] Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. *Circulation.* 2020 May 19;141(20):1648–55.
- [37] Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY. Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection. *J Korean Med Sci.* 2016;31:1717–25.
- [40] Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. *Cochrane Database Syst Rev.* 2013;10.
- [41] Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl).* 2020;133:1039–43.
- [42] Liu K, Fang YY, Deng Y, Liu A, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl).* 2020;133:1025–31. <https://doi.org/10.1097/CM9.0000000000000744>.
- [43] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* 2020 Mar 17;323:1061–9.
- [44] Low-Cost Dexamethasone Reduces Death by up to one Third in Hospitalised Patients With Severe Respiratory Complications of COVID-19. University of Oxford; 2020.
- [45] Huang X, Sun Y, Su G, Li Y, Shuai X. Intravenous immunoglobulin therapy for acute myocarditis in children and adults. *Int Heart J.* 2019;60:359–65. <https://doi.org/10.1536/ihj.18-299>.
- [46] Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. *Crit Care Med.* 2017 Feb;45:e124.
- [47] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. *J Med Virol.* 2020;92:814–8.
- [48] ClinicalTrials.gov. Tocilizumab in COVID-19 pneumonia (TOCIDVID-19) (TOCIDVID19). Identifier: NCT04317092. Updated <https://www.clinicaltrials.gov/ct2/show/NCT04317092.66>; April 7, 2020.
- [49] ClinicalTrials.gov. Tocilizumab for SARS-CoV2 severe pneumonitis. Identifier: NCT04315480. Updated <https://clinicaltrials.gov/ct2/show/NCT04315480.68>; April 13, 2020.
- [50] ClinicalTrials.gov. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. Identifier: NCT04315298. Updated <https://www.clinicaltrials.gov/ct2/show/NCT04315298>; April 6, 2020.
- [51] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19—preliminary report. *N Engl J Med.* 2020;383:1813–26.
- [52] de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proc Natl Acad Sci.* 2020 Mar 24;117:6771–6.